Hengrui Medicine's research results of camrelizumab appeared again at the European Lung Cancer Congress and made a new breakthrough in the treatment of squamous NSCLC!

On March 30, at the 2022 European Lung Cancer Conference (2022 ELCC) being held, Professor Zhou Caicun of Shanghai Pulmonary Hospital affiliated to Tongji University orally reported the latest overall survival (OS) data of the CameL-sq study, attracting experts in the field of lung cancer from all over the world.

The report pointed out that the median OS of camrelizumab combined with chemotherapy group was as long as 27.

The CameL-sq study is a national multicenter, double-blind, randomized controlled phase III trial comparing camrelizumab or placebo in combination with carboplatin and paclitaxel, respectively, in the first-line treatment of stage IIIB-IV squamous non-small cell lung cancer (NSCLC).

New Survival Data Record

New breakthrough in the treatment of squamous NSCLC

According to reports, the research data reported this time is based on the relevant research in 2021, and after continuing to follow up for 1 year, more mature OS data are obtained, and the advantages of the camrelizumab combined chemotherapy group are more significant

As a result, the CameL-sq study has refreshed the current median overall survival record of the phase III randomized controlled trial (RCT) of immunotherapy combined with chemotherapy in the first-line treatment of advanced lung squamous cell carcinoma, and camrelizumab combined with chemotherapy has created a new survival data height (including median OS and 3-year OS rate) [3], bringing a new breakthrough in the field

Longevity reflects the dawn of healing

Lung cancer chronic disease management into reality

Achieving a cure is the ultimate goal of cancer therapy

In the era of chemotherapy, the OS of patients with advanced squamous cell carcinoma of the lung is usually less than 1 year, long-term survival is rare, and cure is even more out of reach; the successful exploration of immunotherapy has brought hope for long-term survival

At the same time, the latest safety data released this time showed that no new safety signals were observed, and the incidences of during-treatment adverse events (TEAEs) and treatment-related adverse events (TRAEs) were comparable between the two groups, adding confidence to patients’ long-term use.

Camrelizumab has achieved outstanding results in the field of lung cancer

Inclusive of Chinese patients

Lung cancer is a malignant tumor with the highest morbidity and mortality in China, with a huge patient base and a heavy disease burden

In 2020, based on the breakthrough data of the CameL study, camelizumab became the first domestic PD-1 monoclonal antibody recommended in the guidelines of the Chinese Society of Clinical Oncology (CSCO) as the first-line standard treatment for advanced driver-negative non-squamous NSCLC, and became the The first Chinese self-developed immune checkpoint inhibitor approved for driver gene-negative advanced non-squamous NSCLC indications was quickly included in the National Medical Insurance Drug List after only half a year, becoming the first reimbursable immune checkpoint in the field of lung cancer Inhibitor, which shows its urgent clinical needs and outstanding clinical value

In 2021, camrelizumab will make a new success.

Up to now, camrelizumab has been approved for a total of 8 indications in the five tumor fields of lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer and lymphoma , leading the domestic PD-1 mAb, and has a number of indications It has been included in the national medical insurance drug list, greatly improving the accessibility of drugs

references:

[1, 2, 3, 4] Zhou CC, et al.

[5] Zhou C, Chen G, Huang Y, et al.

[6] Ren S, Chen J, Xu X, et al.

[7] Jiang T, Chen J, Xu X, et al.
Mol Cancer.
2022;21(1):4